The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
 
Funda Meric-Bernstam
No Relationships to Disclose
 
Richard J. Lee
No Relationships to Disclose
 
Bradley Curtis Carthon
No Relationships to Disclose
 
Othon Iliopoulos
No Relationships to Disclose
 
James Walter Mier
No Relationships to Disclose
 
Manish R. Patel
No Relationships to Disclose
 
Nizar M. Tannir
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
No Relationships to Disclose
 
Naomi B. Haas
No Relationships to Disclose
 
Martin Henner Voss
No Relationships to Disclose
 
James J. Harding
No Relationships to Disclose
 
Ramaprasad Srinivasan
No Relationships to Disclose
 
Geoffrey Shapiro
No Relationships to Disclose
 
Melinda L. Telli
No Relationships to Disclose
 
Pamela N. Munster
No Relationships to Disclose
 
Richard D. Carvajal
No Relationships to Disclose
 
Yonchu Jenkins
No Relationships to Disclose
 
Sam H. Whiting
No Relationships to Disclose
 
Johanna C. Bendell
No Relationships to Disclose
 
Todd Michael Bauer
No Relationships to Disclose